anti-CD3/CD19 bispecific antibody (Curon Bipoharmaceutical)

N/A

Report date: 2026/03/19 16:53:22

Base Information

Drug Nameanti-CD3/CD19 bispecific antibody (Curon Bipoharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT cell surface glycoprotein CD3 modulatorsT lymphocytes stimulants +[4] 
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, FollicularPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCuron Biopharmaceutical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCuron Biopharmaceutical Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A